Scott A. Hammond

Scott A. Hammond's work focuses on cancer immunotherapy, studying how the immune system interacts with tumors and how treatments like checkpoint inhibitors (drugs blocking proteins such as PD-1/PD-L1) and engineered antibody or T-cell-based therapies can be used to fight cancer. Recent research includes analyzing why some tumors develop resistance to immunotherapy, testing new antibody-based drugs in cancer models, and studying immune cells within tumors such as macrophages. This research is largely translational, combining laboratory models with real-world patient data to understand and improve cancer immunotherapies.

Publication output was modest and variable from 2017-2022 but rose sharply starting in 2023, with a large spike that year followed by continued elevated output through 2025, suggesting a recent period of substantially increased research activity.

Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026